[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100545015":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":32,"centralContacts":37,"locations":31,"responsibleParty":47,"collaborators":50,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":67,"eligibilityCriteria":68,"healthyVolunteers":63,"sex":69,"minAge":70,"maxAge":31,"enrollmentInfo":71,"targetDuration":31,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":80,"overallStatus":83,"whyStopped":31,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":31},{"fullName":5,"class":6},"R-Evolution Worldwide S.r.l. Impresa Sociale","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Albendazole and Praziquantel","EXPERIMENTAL","This arm includes combined albendazole with praziquantel, given to approximately 150 participants. Subjects will also receive dexamethasone as an adjunct treatment. An appropriate dose will be calculated per participant's body weight and administered to each participant daily for 10 days. Participants will be monitored for 30 minutes following oral medication, and a repeat dose will be administered if a participant vomits within this observation period. Additional doses (the whole cycle) will be supplied for participants failed to clear NCC in six months.",[13],"Drug: albendazole and praziquantel",{"label":15,"type":16,"description":17,"interventionNames":18},"Albendazole","ACTIVE_COMPARATOR","This arm includes albendazole monotherapy, given to approximately 150 participants. Subjects will also receive dexamethasone as an adjunct treatment. An appropriate dose will be calculated per participant's body weight and administered to each participant daily for 10 days. Participants will be monitored for 30 minutes following oral medication, and a repeat dose will be administered if a participant vomits within this observation period. Additional doses (the whole cycle) will be supplied for participants failed to clear NCC in six months.",[19],"Drug: Albendazole",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","albendazole and praziquantel","Combination of albendazole plus praziquantel",[9],[15,27],"Praziquantel",{"type":22,"name":15,"description":29,"armGroupLabels":30,"otherNames":31},"Albendazole alone",[15],null,[33],{"name":34,"affiliation":35,"role":36},"Kabemba E. Mwape, Prof.","University of Zambia","PRINCIPAL_INVESTIGATOR",[38,43],{"name":39,"role":40,"phone":41,"phoneExt":31,"email":42},"Bernard J. Ngowi, Dr","CONTACT","+255 252500082","Ngowi.Bernard@udsm.ac.tz",{"name":44,"role":40,"phone":45,"phoneExt":31,"email":46},"Helena A. Ngowi, Prof.","+255 232640037","helenangowi@gmail.com",{"type":36,"investigatorFullName":48,"investigatorTitle":49,"investigatorAffiliation":5,"oldNameTitle":31,"oldOrganization":31},"Dario Scaramuzzi","Director",[51,53,56,58,59],{"name":52,"class":6},"Muhimbili University of Health and Allied Sciences",{"name":54,"class":55},"National Institute for Medical Research, Tanzania","OTHER_GOV",{"name":57,"class":6},"Sokoine University of Agriculture",{"name":35,"class":6},{"name":60,"class":6},"University Ghent","100545015","phase-4-assessment-of-combined-praziquantel-and-albendazole-vs-albendazole-alone-to-treat-active-parenchymal-neurocysticercosis-100545015",false,"NCT06376396","Assessment of Combined Praziquantel and Albendazole vs Albendazole Alone to Treat Active Parenchymal Neurocysticercosis","Assessment of Combined Antiparasitic Drugs Praziquantel and Albendazole Versus Albendazole Alone in the Treatment of Active Parenchymal Neurocysticercosis in Tanzania and Zambia","NeuroSolve","Inclusion Criteria:\n\n* Living in the study area for a continuous period of 3 years\n* Adult aged 18 years and above\n* Are willing and able to consent to this study\n* Meet the definitions of active symptomatic NCC\n* Have late onset of epilepsy or history of seizures, epileptic seizures\n* Subjects willing to undergo diagnostic procedures\n* Subjects medically stable enough for trial medication to be initiated\n* Subjects willing to be hospitalized for 11-20 days to receive treatment for NCC\n* Subjects willing to be followed up for one year following receipt of study medication\n\nExclusion Criteria:\n\n* Women pregnant or breastfeeding\n* Symptomatic NCC with cysts in extra-parenchymal location (sub-arachnoid and\u002For ventricles)\n* Have uncontrolled hypertension and\u002For diabetes\n* Have chronic consuming illness such as cancer or mental handicap to not allow them to follow the study instructions\n* Have severe immunodeficiency eg. HIV\u002FAIDS or Autoimmune diseases\n* Already known allergies to albendazole or praziquantel\n* Subject taking part in another clinical\u002Fpharmacological study in the 30 days preceding enrollment","ALL","18 Years",{"count":72,"type":73},300,"ESTIMATED","INTERVENTIONAL",[76],"PHASE4","The goal of this clinical trial is to compare the combination albendazole and praziquantel versus albendazole alone in patients affected by neurocysticercosis.",[79],"Neurocysticercosis",[81,82],"Neglected Tropical Disease","Epilepsy","NOT_YET_RECRUITING","2024-04-19",{"date":86,"type":87},"2024-04-23","ACTUAL",{"date":89,"type":73},"2024-06",{"date":91,"type":73},"2026-12",{"name":5,"class":6}]